In contrast to these studies, however, others have provided evidence that PPARβ/δ activation promotes lung cancer; the agonist GW501516 stimulates proliferation, inhibits apoptosis, and supports anchorage-independent growth of A549, H157, and H23 NSCLC cells [25]. Here, PPARD is linked to non-small cell lung carcinoma.